Stockwinners Market Radar for July 07, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:25 EDT New York AG confirms bipartisan antitrust suit against Google - New York Attorney General Letitia James said she is co-leading a bipartisan coalition of 37 attorneys general in filing a lawsuit against Google LLC for its "illegal and anticompetitive conduct that has sought to maintain the company's monopoly power in the mobile app distribution and in-app payment processing markets." "Through a series of exclusionary contracts and other anticompetitive conduct in the Google Play Store, Google has deprived Android device users of robust competition that could lead to greater choice and innovation, as well as significantly lower prices for mobile apps," James' office said in a statement. "Attorney General James and the coalition - co-led by the attorneys general of Utah, North Carolina, and Tennessee - also accuse Google of requiring app developers selling in-app digital content through apps purchased via Google's Play Store to use Google Billing as a middleman, forcing app consumers to pay Google's commission - up to 30 percent - indefinitely."

17:56 EDT SciPlay bought Finland-based 'casual game developer' Koukoi Games Oy, no terms - SciPlay acquired Finland-based developer and operator of casual mobile games Koukoi Games Oy The Koukoi team will take over the organic build of a new casual game concept, a key step in SciPlay's expansion in the casual genre and revenue diversification strategy to drive long-term growth and shareholder value. Koukoi, located in Oulu, Finland, brings an experienced and talented team that developed the hit title Om Nom Run which has been downloaded over 30M times. Koukoi's casual mobile games are built on their proprietary technology platform that includes modular game feature components and real-time multiplayer engines that can be used across games. The combination of Koukoi's technology platform and SciPlay's data driven "Engine" will be the foundation of SciPlay's drive to further expand in the $20B+ casual gaming genre. This is SciPlay's third acquisition. The Company acquired Spice Rack and its popular bingo game Bingo Showdown in 2017, more than tripling the games revenue. In addition, the Company acquired Come2Play in 2020, which currently is in soft launch with Solitaire Pets Adventure. SciPlay will utilize the same successful model to bring Koukoi into its portfolio. The transaction closed effective July 2 and does not materially impact the Company's liquidity position, which is over $400M with no debt on the balance sheet. Financial details of the transaction are not being disclosed.

17:17 EDT BAE Systems awarded $600.28M Army contract - BAE Systems was awarded a $600.28M cost-plus-fixed-fee contract in support of the Armored Multi-Purpose Vehicle and M113 Family of Vehicles. Bids were solicited via the internet with one received. Work locations and funding will be determined with each order, with an estimated completion date of July 6, 2026. U.S. Army Contracting Command is the contracting activity.

17:03 EDT AptarGroup, YAT announce skincare collaboration - AptarGroup and YAT, an online skincare solutions company, have announced a strategic collaboration that aims to develop a range of products and services for the skincare market. This partnership will bring together YAT's product design and concept development capabilities and Aptar's packaging and dispensing solutions. Aptar will leverage YAT's market insight database, focused on specific consumer skincare needs and skincare profiles, and will use YAT's experience in customized solutions as well as online product distribution and promotion to bring new solutions to market. The company said this collaboration will bolster Aptar's product and service offerings in China.

16:57 EDT Overstock.com jumps over 3% after being initiated as Conviction Buy at Needham - Shares of Overstock.com are up 3.2% at $88.72 after-hours after being initiated at Buy by Needham with an addition to its Conviction List.

16:32 EDT Valaris awarded contract extension from Valaris - Valaris has been awarded a 183-day extension to its contract with Aramco for Valaris JU-140, a standard-duty modern jackup. The extension is in direct continuation of the existing contract and, as a result, the Valaris JU-140 is now expected to be under contract through the end of 2021.

16:24 EDT Bentley Systems announces Seequent's acquisition of Aarhus GeoSoftware - Bentley Systems' Seequent business unit has acquired Danish company Aarhus GeoSoftware, a developer of geophysical software. The acquisition extends Seequent's solutions for operational ground water management, and for sustainability projects involving exploration, contaminants, and infrastructure resilience. Aarhus GeoSoftware, a spinoff company from Aarhus University in Denmark, develops the software packages AGS Workbench, SPIA, Res2DInv, and Res3DInv for the processing, inversion, and visualization of geophysical data from ground-based and airborne electromagnetic, electrical resistivity tomography remote sensing, and other sources. Airborne Electromagnetic remote sensing uses electromagnetic induction to collect extensive volumes of data from an aircraft.

16:20 EDT American Assets Trust acquires Eastgate Office Park in Washington - American Assets Trust has closed on the acquisition of Eastgate Office Park, consisting of an approximately 280,000 square foot, multi-tenant office campus in the premier I-90 corridor submarket of Bellevue, Washington. Eastgate Office Park is currently greater than 95% leased to a diversified tenant base with a weighted average lease term of approximately 3 years with contractual lease rates that the company views as below prevailing market rates for the submarket. The purchase price of $125M was paid with cash on hand.

16:17 EDT Camping World announces investment in Happier Camper - Camping World "is pleased to announce a strategic investment in Los Angeles-based, Happier Camper, Inc., the developer of the innovative and patented modular van conversion system - Adaptiv for vans. This partnership will deliver the Adaptiv system and technology products for van and camper conversions to nationwide Camping World SuperCenters. The locations will serve as design, install and renovation centers by 2022."

16:09 EDT SI-Bone publishes SALLY study results, showing improvement in SI pain - SI-Bone announced the publication of 2-year results from SALLY study of bone growth in the Sacroiliac Joint after Minimally Invasive Surgery with Titanium Implants, ClinicalTrials.gov NCT 03122899, a prospective multicenter clinical trial of the iFuse-3D Implant System. Clinical results at 24 months showed marked and sustained improvements in sacroiliac, SI joint pain, patient function and quality of life that are consistent with results from three prior multicenter prospective clinical trials using the iFuse implant. Results also demonstrated a significant reduction in the proportion of study subjects taking opioids for SI joint pain In addition, the study included three objective physical function tests , all of which showed statistically significant improvements from baseline. An earlier publication of 12-month results from SALLY reported radiographic analysis of CT scans showing accelerated bony bridging across the SI joint compared to the iFuse implant. 100% of treated SI joints showed bone integration to the iFuse-3D implant surface on both the sacral and iliac side, and 77% of treated joints showed bony bridging across the joint. "These 24-month results from the SALLY study show that the 3D-printed iFuse-3D implant provides the same early and sustained clinical benefits as those demonstrated in two prior RCTs2,3 and one large multicenter prospective trial4 using the original iFuse implant," said Vikas Patel, MD., Department of Orthopedics at University of Colorado and study principal investigator. "Furthermore, the early results from radiographic analysis of implant bone integration and SI joint bony bridging indicate that the enhanced porous surface of the iFuse-3D implant combined with the fenestrated structural design accelerates the rate of intraarticular fusion compared to the iFuse implant."

16:08 EDT Codexis earns milestone payment from GlaxoSmithKline - Codexis (CDXS) announced it earned a milestone payment related to the licensing of its proprietary CodeEvolver protein engineering platform technology to GlaxoSmithKline (GSK). This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve astep in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in Q2.

16:06 EDT Qiagen launches Workflow Configurator - Qiagenn announced the launch of the Workflow Configurator, enabling researchers in the life sciences to easily and quickly find the best solutions to optimize their experiments. Customers simply choose their application, biological starting material, analyte and analysis type. In seconds, the configurator sorts through hundreds of potential products to find the most suitable workflow and associated products. The Workflow Configurator also offers direct purchase and sales support. "QIAGEN knows discoveries take careful workflow planning and optimization, and we design our solutions with this in mind. The QIAGEN Workflow Configurator is an uniquely useful digital solution that makes researchers' day-to-day laboratory routine more efficient and productive, even with the most challenging samples," said Thomas Schweins, Senior Vice President of the Business Area Life Sciences of QIAGEN. "Digital tools are of tremendous importance for the Life Sciences industry. QIAGEN is also investing in multiple other industry leading activities such as QIAGEN Digital Insights - which offers unique integrated data assets combined with deep analytical skills - or GeneGlobe - the leading gene-design, customization and analysis platform."

16:02 EDT Geospace acquires Aquana LLC - Geospace Technologies announced that it has acquired 100% of the outstanding shares of Aquana, LLC, a comprehensive wireless water monitoring and control system provider. Under terms of the agreement, Aquana will operate as a wholly owned subsidiary of Geospace Technologies. The company intends to retain Aquana's employees, further strengthening Geospace's highly skilled technical workforce. Terms of the transaction include an initial cash payment of $1.4M at closing, subject to adjustment, and additional contingent cash payments over a six-year earn-out period. The contingent cash payments will be derived from revenues generated during the earn-out period from products and services sold by Aquana, LLC.

16:01 EDT Fox Corp. hires Brian Nick as Chief Communications Officer - Fox Corporation (FOXA, FOX) announced the company's new head of communications. Brian Nick has been named Executive Vice President and Chief Communications Officer. The role will be based in Los Angeles and will report to Lachlan Murdoch, Chairman and CEO of Fox Corporation. Nick will join FOX from Coca-Cola Consolidated (COKE), where he leads all internal and external communications. He begins his new role with FOX at the end of July.

15:36 EDT Quidel recalls Lyra SARS-CoV-2 Assay due to 'significant' false negative risk - According to the FDA, Quidel is recalling the Lyra SARS-CoV-2 Assay due to a "significant" risk of false negative results for patients with relatively high amounts of SARS-CoV-2 virus potentially causing the PCR amplification to occur before a cycle-threshold value less than or equal to5 when using the following thermocyclers: ThermoFisher QuantStudio 7 Pro, Applied Biosystems 7500 Fast Dx, Applied Biosystems 7500, Bio-Rad CFX96 Touch, Roche LightCycler 480, or Qiagen RotorGene MDx. False negative results may lead to delayed diagnosis or inappropriate treatment of SARS-CoV-2 that may cause patient harm, serious illness, and death. False negative results can also lead to further spread of the SARS-CoV-2 virus, when presumed negative patients are introduced into groups within health care, long-term care, or other similar facilities. Actions to limit exposure based on false negative results might not be taken, such as isolating infected individuals. Quidel has received five complaints about the Lyra SARS-CoV-2 Assay, however, there have been no reports of injuries or death from this issue. Reference Link

15:08 EDT FCC proposes fine against Gray Television for media ownership violation - FCC adopts a Notice of Apparent Liability and Forfeiture against Gray TV, licensee of stations KYES-TV, Anchorage, AK and KTUU-TV, Anchorage, AK, for its apparent violation of the prohibition against owning two top-four television stations in the same DMA. Reference Link

13:43 EDT Inter Parfums, Salvatore Gerragamo sign agreement for fragrance business - Inter Parfums (IPAR) announced that Salvatore Ferragamo (SFRGF), the parent company of the Salvatore Ferragamo Group, and Inter Parfums have signed a transaction agreement whereby an exclusive and worldwide license will be granted for the production and distribution of Ferragamo brand perfumes. The license will be effective from October 2021 and will last for 10 years with a 5-year optional term, subject to certain conditions. With reference to the management and coordination of activities related to the license agreement, Inter Parfums, Inc. will operate through a wholly-owned Italian company, based in Florence, and will also guarantee the production in Italy. "Inter Parfums' great competence and recognized creativity make it the ideal partner to preserve the values and heritage of our brand with Made in Italy products. Its great commercial expertise will also ensure a new boost to the business of our fragrances, which will be distributed through a carefully selected sales network," commented Leonardo Ferragamo, President of Salvatore Ferragamo S.p.A.

13:03 EDT Bowl America holder Anita Zucker seeks alternative to Bowlero merger - Anita Zucker, owner of 279,596 shares of 7.5% Bowl America (BWL.A), says she was "disappointed by the board's decision to sell the Company at what she believes to be a severely depressed price." Bowl America disclosures in the proxy statement "only confirmed her fears concerning the board's decision. In addition, she believes that the proxy statement omits or misrepresents material information necessary for Bowl America's shareholders to make an informed decision as to how to vote," Zucker said in a regulatory filing. Zucker demanded that the board amend the proxy "so that it is not false and misleading via a letter from her counsel." Zucker is currently considering "all options available to her to protect her significant investment in the Company and is committed to taking all necessary actions to create an alternative to the Bowlero (BOWL) Merger that maximizes value for all Company shareholders."

12:19 EDT Amazon introduces Amazon Advertising Partner Network - Amazon introduced the Amazon Advertising Partner Network, a global community of agencies and tool providers that can help advertisers achieve their business goals using Amazon Advertising products. This new program helps agencies and tool providers deliver results for Amazon's mutual advertising customers, the company said. The Partner Network enables partners to further develop their capabilities, engage more deeply with Amazon Advertising, and grow their businesses. "We're thrilled to continue working closely with agencies and tool providers to help them better serve our mutual customers and grow their businesses," said Aby Angilivelil, director of partner development at Amazon Advertising. {We've listened closely to partner feedback and have worked hard to build an experience that better meets their needs. The Partner Network and its range of resources is our first step towards helping partners scale their expertise and solutions across all of our advertising products. We'll continue collaborating with partners to help them meet advertisers' business goals, and we're excited by what's yet to come." Reference Link

12:10 EDT Yandex, Grubhub partner on robot delivery on U.S. college campuses - Yandex Self-Driving Group (YNDX) announced a multi-year partnership with Grubhub (GRUB). The partnership between Grubhub and Yandex SDG will create faster and more cost-effective deliveries on college campuses in the United States, the companies said. Yandex autonomous delivery robots will join Grubhub's food delivery platform built specifically for life on campus. Grubhub partners with more than 250 college campuses across the US, giving students the ability to integrate meal plans directly into their Grubhub account and access restaurants both on and off campus for delivery and pickup. Grubhub and Yandex SDG will be rolling out delivery by autonomous robots at select campuses later this fall. "We chose to partner with Grubhub for campus delivery because of Grubhub's unparalleled reach into college campuses across the United States, as well as the flexibility and strength of their ordering platform. We are delighted to deploy dozens of our rovers, taking the next step in actively commercializing our self-driving technology in different markets across the globe,'' said Dmitry Polishchuk, CEO of Yandex Self-Driving Group.

12:00 EDT Nam Tai Property falls -9.5% - Nam Tai Property is down -9.5%, or -$2.08 to $19.80.

12:00 EDT Express falls -9.8% - Express is down -9.8%, or -57c to $5.24.

12:00 EDT Peabody Energy rises 15.2% - Peabody Energy is up 15.2%, or $1.22 to $9.26.

11:52 EDT SEC announces settlement with Parallax over 'misleading statements' - The Securities and Exchange Commission announced charges against Parallax Health Sciences "for making misleading statements about its efforts to fight COVID-19." The SEC also charged Parallax's Chief Executive Officer Paul Arena and its Chief Technology Officer Nathaniel Bradley for their roles in the statements. Each party has offered to settle the charges. The SEC temporarily suspended trading in Parallax's common stock on April 10 due to questions about the accuracy of the company's statements. Without admitting or denying the SEC's allegations, Parallax, Arena, and Bradley consented to judgments permanently enjoining them from future violations of the charged provisions and requiring them to pay penalties of $100,000, $45,000, and $40,000, respectively. Arena also agreed to be prohibited for five years from acting as a public company officer or director and from participating in an offering of penny stock. Bradley, who the SEC says assisted Arena in drafting two of the misleading press releases, agreed to be prohibited for three years from participating in an offering of penny stock. The settlements are subject to court approval. Reference Link

11:38 EDT MetLife announces enhanced pet insurance offering - MetLife (MET) announced its introduction of a "new, innovative pet insurance offering" that it said "offers a range of features at highly competitive rates available to dogs and cats of all ages and breeds." The company said: "MetLife Pet Insurance is also available as an employee benefit at discounted rates10. When obtaining coverage through their employer, employees who already have pet insurance with another insurance carrier will be able to switch to MetLife with the assurance that their pets' pre-existing conditions1 will be covered. MetLife Pet Insurance is the only carrier in the industry to offer this benefit." Shares of Trupanion (TRUP), which provides medical insurance for cats and dogs on monthly subscription basis, are down $3.02, or nearly 3%, to $117.27 in late morning trading.

11:34 EDT LendingClub settles case with FTC in California court - A document filed with the U.S. District Court for California's Northern District in a case between the Federal Trade Commission and Lending Club stated: "The court vacates the July 14, 2021 settlement conference because the parties settled the case subject to the contingency of approval of the Commission. For now, they have asked that the other case-related deadlines remain in place."

11:06 EDT Bionano Genomics announces publications on optical genome mapping - Bionano Genomics announced that two peer-reviewed studies from world renowned scientists and clinicians from prestigious institutions in Europe including Radboud University Medical Center, Cochin Hospital in Paris, Hospices Civils in Lyon and the University Hospital of Clermont-Ferrand were published back-to-back in the American Journal of Human Genetics. One study analyzed the genomes of patients with inherited genetic disease and one study those of hematological malignancies. These seminal papers outline the utility of optical genome mapping as a superior alternative to traditional methods for structural variant analysis. The results showed OGM was 100% concordant with findings from fluorescent in-situ hybridization , karyotype, and CNV-microarray when these traditional methods identified one or more pathogenic variants in samples from study subjects. Additionally, the higher resolution of OGM for all types of variants relative to traditional cytogenomics techniques allowed for a more precise characterization of breakpoints and the identification of genes they affect, the detection of smaller cancer-associated events that usually escape detection by traditional means, and the discovery of additional complexity of rearrangements. Among the key conclusions presented in both studies, is that OGM has the potential to become a primary analysis for most molecular cytogenetics applications and provides a complement to existing sequencing-based methods for a more comprehensive view of genome variation. The authors describe OGM as a better alternative to traditional cytogenetics assays for both inherited genetic disease and hematological malignancy applications since it consolidates multiple antiquated methods requiring manual integration for interpretation into a single workflow with higher resolution for detection of all classes of SVs. Additionally, the authors highlight that the OGM workflow is ready to implement into routine clinical practice and that data can be easily analyzed by lab-oriented personnel, which is of crucial importance for clinical adoption and distinguishes OGM from sequencing-based methods which require complex analytical pipelines and specialized bioinformatic teams. The study of 52 hematological malignancy samples led by Dr. Alexander Hoischen from Radboud University Medical Center, Nijmegen, The Netherlands, analyzed a wide variety of myeloid and lymphoid samples, representing the full range of hematological malignancy patients referred to the clinic.

10:43 EDT GoDaddy announces launch of service to sell unused domain names - GoDaddy announced the launch of List for Sale, a service that it said "enables anyone to quickly and easily list and sell unused domain names." List for Sale is a free service for GoDaddy customers. "Customers only pay the industry standard sales commissions, ranging between 10-20%, to Afternic if the domain is sold," the company said.

10:29 EDT ServisFirst Bank announces opening of international department - ServisFirst Bank recently announced the opening of an International Department to be led by Tara Herd. The International Department will provide multiple product offerings to ServisFirst Bank's commercial customers including international and domestic standby letters of credit, import and export letters of credit, documentary collections, international wires, and foreign exchange. The International Department staff will consist of an experienced team with many years of product knowledge, product delivery and outstanding service. Tara Herd joins ServisFirst Bank as Senior Vice President and International Department Manager. In this role, she will manage operations including trade finance, foreign exchange trading and operations, and international wires while supervising the administration of existing products and services. Prior to joining ServisFirst Bank, Herd served in leadership positions at Synovus Financial Corporation, First Commercial Bank, and AmSouth Bank in Birmingham, Alabama.

10:06 EDT Siemens Mobility announces award of $3.4B in contracts from Amtrak - Siemens Mobility announced it has been awarded $3.4B in contracts in the United States to design, manufacture and technically support 73 multi-powered trains for Amtrak, the National Railroad Passenger Corporation. The order includes dual power and hybrid battery trains. The first will be delivered in 2024, while the first of its kind Venture Hybrid battery train will begin testing in 2025. The trains for the Northeast Corridor and State Supported routes will be delivered from 2024 through 2030. There is also a possibility for up to 140 additional trains and further maintenance agreements. "The order is the Railroad's latest endeavor to acquire the most sustainable and efficient trains on the market, which include dual powered and hybrid battery vehicles," Siemens stated. Reference Link

10:02 EDT CAS Investment Partners to nominate slate of candidates for At Home Group - CAS Investment Partners, which beneficially owns approximately 17% of the outstanding common stock of At Home Group, announced its intent to nominate a slate of highly-qualified and independent candidates for election to the Company's Board of Directors at the 2021 Annual Meeting of Stockholders in the event that the tender offer initiated by funds advised by Hellman & Friedman fails. Clifford Sosin, Founder and Portfolio Manager of CAS, commented: "We want to offer our fellow stockholders a viable alternative to the insufficient $37 per share tender offer initiated by H&F. As outlined in our detailed presentation and prior letters, we firmly believe At Home is a winning retailer on a path to significant near-term stock price appreciation. This is why we plan to nominate a slate of highly-qualified and independent director candidates for election to At Home's Board if stockholders reject H&F's tender. Our prospective slate will be committed to creating enduring value for the Company's stockholders, including through potential dividends and stock repurchases, while also remaining open-minded when it comes to exploring viable strategic alternatives. CAS is committed to having a principal serve on its slate and remaining a long-term stockholder if it elects directors to the Board. It has become absolutely clear to us that the current Board cannot be trusted to act in the best interests of the Company's stockholders given its approval of this grossly undervalued transaction. Fresh perspectives are clearly required in the boardroom."

10:00 EDT Nam Tai Property falls -6.5% - Nam Tai Property is down -6.5%, or -$1.43 to $20.45.

10:00 EDT GasLog Partners falls -9.1% - GasLog Partners is down -9.1%, or -46c to $4.57.

10:00 EDT Daqo New Energy rises 11.0% - Daqo New Energy is up 11.0%, or $7.36 to $74.19.

09:47 EDT AMC Entertainment falls -4.2% - AMC Entertainment is down -4.2%, or -$2.11 to $47.85.

09:47 EDT Ellington Financial falls -5.0% - Ellington Financial is down -5.0%, or -95c to $17.93.

09:47 EDT JinkoSolar rises 9.1% - JinkoSolar is up 9.1%, or $4.95 to $59.30.

09:43 EDT Great Wall Motor to invest RMB 100B in R&D - Recently, GWM held the 8th Technology Festival in Baoding at its headquarters. At the opening ceremony, GWM Chairman Jack Wei emphasized the next-generation clean energy-driven smart cars would constitute the new pattern in future automobile industry development. GWM plans to invest RMB 100B in R&D in the coming five years for NEVS and smart vehicles, offering more environment-friendly, smarter and safer products for global users.

09:39 EDT Accelerate Diagnostics launches PhenoTest BC kit in the U.S. - Accelerate Diagnostics earlier announced the launch of a new IVD configuration of its Accelerate PhenoTest BC kit in the United States. With this launch, the company now provides two solutions for fast sepsis testing, the company said in a statement. "This product expansion provides new options for customers to access the proven benefits of our fast susceptibility testing," said Jack Phillips, CEO of Accelerate Diagnostics. "Overall market feedback has been positive, especially from customers who already have a rapid ID system but who still need fast susceptibilities to support getting patients on the right therapy as soon as possible. Based on the strong interest we are seeing, together with improved customer access, we believe this new AST configuration will drive our sales funnels, Pheno placements and future revenues."

09:37 EDT BioSig Technologies installs signal processing technology in NYC hospital - BioSig Technologies announced that the Company installed its technology in a leading New York City hospital. The PURE EP is a non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. To date, more than 50 physicians have completed over 1,000 patient cases with the PURE EP System across twelve clinical sites.

09:33 EDT Atossa receives regulatory approval to open study of AT-H201 in Australia - Atossa Therapeutics announces it has received regulatory approval from HREC to open a clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for "long-haul" patients with post-infection pulmonary disease. The Phase 1/2a placebo-controlled study will enroll a total of 60 healthy participants and moderately-ill hospitalized COVID-19 patients. The study has 4 parts: a single ascending dose part, a multiple ascending dose part, a combination part in healthy individuals and a combination in COVID-19 infected patients and will be conducted with Avance Clinical Pty Ltd., a leading Australian clinical research organization. AT-H201 is a proprietary combination of two drugs previously approved by the FDA to treat other diseases and by other administration routes. AT-H201 is intended to be inhaled via a nebulizer to improve compromised lung function for moderate to severely ill, hospitalized COVID-19 patients and for "long-haul" patients with post-infection pulmonary disease. In May 2020, we completed in vitro testing of AT-H201 which showed that the components of AT-H201 inhibit SARS-CoV-2 infectivity of VERO cells, which is a standard cell type being used to study infectivity of the coronavirus. The AT-H201 components were found to be at least four times more potent than Remdesivir and at least 20 times more potent than Hydroxychloroquine. Potency was measured by microscopic examination of the cytopathic effect caused by SARS-CoV-2 in VERO cells. The Phase 1/2a study in Australia and other clinical studies must be successfully completed and regulatory approvals must be obtained before AT-H201 may be commercialized. No assurance can be given than studies will be successful or that regulatory approvals will be obtained.

09:29 EDT Tantech Holdings subsidiary fulfills fuel midibus order, exports to Middle East - Tantech Holdings announced that its subsidiary, Shangchi Automobile Co, fulfilled a new customer order for its medium-sized fuel bus for export to the Middle East. Wangfeng Yan, Chief Executive Officer of Tantech, said, "We are very pleased with customer demand levels and the continued diversification of our business. There is continued strong global demand for feature-rich fuel busses capable of transporting large groups of people in a comfortable environment. This is a large, near-term opportunity for us, along with vehicles we are developing with our other teams, including the street sweeper and industrial vehicle market, which will allow us to expand our scale, manufacturing expertise and brand visibility as we work to build value for the Company and shareholders."

09:25 EDT City of Albany to use Rekor One vehicle recognition system - Rekor Systems announced the selection of its Rekor One vehicle recognition system by the City of Albany, New York, in partnership with the Albany Police Department. Rekor was selected after a competitive bid process in June 2021 to help maintain the safety and security of the community and its citizens. Albany is New York's capital city and part of the economic and cultural core of the Capital District, the third most populous metropolitan region in the state. Rekor One will assist Albany's law enforcement efforts to deter criminal activities and will serve as a forensic tool to help solve crimes after they occur.

09:24 EDT IEC Electronics receives contract award valued in excess of $45M - IEC Electronics announced that it has been awarded a multi-year contract, valued in excess of $45 million, from a Tier 2 Department of Defense contractor. This award is a follow-on order extending IEC's participation with a program it has supported for several years. In 2019 the contractor awarded IEC the entire outsourcing of this program associated with secured communications equipment for U.S. aircraft, ground vehicles and surface warships.

09:22 EDT Akari Therapeutics announces private placement - Akari Therapeutics announced that it has entered into definitive securities purchase agreements with certain accredited and institutional investors, led by existing investors of the Company, including Dr. Ray Prudo, the Company's Chairman, to receive gross proceeds of approximately $12M through a private placement of its equity securities. In connection with the offering, the Company will issue unregistered American Depository Shares, each representing 100 of the Company's ordinary shares, at a purchase price of $1.55 per ADS. The closing of the offering is expected to take place during or before the week of July 12, 2021, subject to the satisfaction of customary closing conditions.

09:20 EDT Berkshire Gray announces completion of Robotics Innovation Center - Berkshire Grey announced the completion of its new Robotics Innovation Center and headquarters in Bedford, MA. The new center showcases Berkshire Grey's capabilities for customers, partners, and investors. The Bedford-based Robotics Innovation Center and headquarters is located at 140 South Road. The new center complements other design and test facilities in the region and provides a focal point for customers, investors, and technical activities. Today, Berkshire Grey has US offices in Bedford, MA, Lexington, MA, and Pittsburgh, PA. Internationally, Berkshire Grey's EMEA headquarters is in Reading, UK. The company also has subsidiaries in Canada and Japan, as disclosed in May. As previously announced, on February 24, 2021, Berkshire Grey entered into a definitive agreement with Revolution Acceleration Acquisition Corp that is expected to result in Berkshire Grey becoming a publicly listed company early in the third quarter of 2021, subject to the satisfaction of customary closing conditions, including approval by the stockholders of Revolution Acceleration Acquisition Corp.

09:16 EDT Dogness International ships 700 cartons of pet products to Japanese partner - Dogness announced it shipped 700 cartons of the company's traditional pet products to one of its long-term strategic partners in Japan for sale. The company noted it is continuing to benefit from strong demand in key markets worldwide led by China, the U.S., Japan and Europe, with significant growth in other countries including Egypt, Russia, Germany, Panama, Australia and New Zealand. Silong Chen, Chairman and Chief Executive Officer of Dogness, commented, "Our team has been working closely with our customers and supply chain partners to ensure we can seamlessly meet the high demand levels we are seeing in Japan. Pet owners are turning to Dogness for high-quality traditional pet products and innovative smart pet tech products that can bring greater happiness, safety and health to their pets. We take pride in supporting stronger pet and owner bonds. We expect to build on our momentum with some very exciting new product launches planned for later this year that will leverage advances in tracking, water and food monitoring, robotics and AI."

09:14 EDT Wyndham announces first property under trademark collection in Hungary - Wyndham Hotels & Resorts announced the opening of H2 Hotel Budapest, Trademark Collection by Wyndham, the latest addition in Wyndham's portfolio of Trademark properties across Europe and its first property under the Trademark Collection brand in Hungary. Christian Michel, Vice President for Development in Europe, Wyndham Hotels & Resorts said: "The Trademark Collection by Wyndham brand has been instrumental in our overall growth strategy in Europe and around the world. We are thrilled to be expanding the brand into such an exciting destination like Hungary while simultaneously supporting our overall conversion strategy. Our relationship with H-Hotels.com has been key in the development of our Trademark by Wyndham Collection across Europe and we look forward to continuing our fruitful collaboration to bring the brand to even more travelers."

09:12 EDT Acurx files provisional patent application for ibezapolstat - Acurx Pharmaceuticals announced that it has filed a provisional patent application in the United States Patent and Trademark Office. The filing of this patent application relates to ibezapolstat and its use to treat C. difficile Infection while reducing the recurrence of the infection, as well as improving the health of the gut microbiome. This is the latest in the series of patent applications that Acrux has filed to protect its proprietary technologies in the field of antimicrobials. Acurx is commencing a Phase 2b clinical trial in patients with CDI during the second half of this year after having recently completed a Ph2a clinical trial which demonstrated that 10 of 10 patients with CDI met the study's primary and secondary efficacy endpoints of Clinical Cure at end of treatment and Sustained Clinical Cure with no recurrence of CDI at the 28-day follow-up visit. Acurx continues to pursue protection for its technologies in the United States and internationally. Acurx aims to protect the technology, inventions, know-how, and improvements that are important to the development of its business using the most effective intellectual property instruments.

09:11 EDT Virpax submitted a pre-IND briefing document to FDA for MMS019 - Virpax Pharmaceutical is providing a progress update on its pipeline of product candidates following the Company's initial public offering in mid-February. Chairman and CEO Anthony P. Mack commented, "Our goal following our IPO was to become a clinical stage company as quickly as possible while preserving our cash and utilizing grants to fund product development efforts where appropriate. To date, I believe we have made solid progress towards these goals. We are making refinements to some formulations which we believe will improve manufacturability, and possibly extend patent life. We are also evaluating additional indications for our unique delivery technologies. Finally, we plan to begin initial Investigational New Drug Application enabling studies shortly on several of our existing programs and recently submitted a pre-IND briefing document to the U.S. Food and Drug Administration, FDA, for MMS019, our intranasal molecular masking spray."

09:09 EDT Tecogen files provisional patent for new hybrid drive - Tecogen is pleased to announce the filing of a provisional patent application entitled "High Efficiency Hybrid Engine-Driven Variable Frequency Drive." The application describes a novel system for seamlessly blending multiple power sources in any combination through a single inverter. The system will allow building owners to energize loads such as a chiller plant from an engine generator system, the existing electric utility, and/or solar and battery storage. The hybrid drive based air-cooled chiller will allow customers to obtain maximum savings while having the added benefit of resiliency from multiple power sources. As the world moves towards a zero-carbon future many utilities are incentivizing microgrid and edge-of-grid solutions to shed load during peak times. Tecogen is already a recognized leader in microgrids, and the hybrid drive will allow customers with grid connections to seamlessly shed excess load on request and receive payments from utilities for doing so.

09:08 EDT IMAC announces next four location of 'The Back Space' centers - IMAC Holdings (IMAC) announces the next four locations of "The Back Space" retail healthcare centers specializing in chiropractic and spinal care services. IMAC's wholly owned subsidiary, The Back Space, will open three additional Nashville-area locations to complement the first opened last month. A second location in Murfreesboro, followed by a La Vergne and Antioch location are anticipated this quarter. Chesterfield, Missouri, home to the Ozzie Smith IMAC Regeneration Center, is the fourth announced location. IMAC's The Back Space, which has now announced five of the 10 locations in a pilot program directly within a Walmart (WMT) retail store, delivers chiropractic adjustments, nerve and muscle stimulation, and percussion tool therapies for soft tissue recovery, muscle relaxation, and spinal wellness. Services will be offered on a walk-in and appointment basis, priced at $25 per treatment, with memberships available for $65 per month that are valid at any The Back Space location.

09:06 EDT First Horizon releases 2020 Corporate Social Responsibility report - First Horizon Corporation released its 2020 Corporate Social Responsibility Report highlighting the merger of equals with IBERIABANK Corporation and its continued commitment to Environmental, Social and Governance efforts. The report provides an update on the meaningful impact the company is making today, and the foundation it is creating for a better future, including the company's efforts to advance its ESG practices and priorities.

09:05 EDT Seanergy Marine to acquir additional capesize vessel and sell oldest vessel - Seanergy Maritime has entered into a purchase agreement with a major Japanese company to acquire a 2009-built Capesize vessel. In addition, Seanergy has entered into a sales agreement with a far-eastern company for the sale of the 2001-built M/V Leadership, the oldest vessel in the company's fleet, for $12M. The substitution of the M/V Leadership with the Capesize vessel will improve Seanergy's average fleet age. The total Capesize acquisition capex for the company year to date adds up to approximately $160M and are fully funded through the company's cash reserves and recently concluded debt financings.

09:02 EDT BM Technologies announces GoAskJay as Workplace Banking partner - BM Technologies announced GoAskJay, a direct-to-consumer insurance & financial marketplace tailored for any stage of your life or business, as a new Workplace Banking platform partner. BM Technologies' Workplace Banking is a financial wellness service that offers innovative banking products to employees. This collaboration marks GoAskJay's first digital banking product offering, which will be available to its approximately three million users in the U.S. GoAskJay offers services that are both customized and bundled, which meet the needs of its customers and become embedded in their lives.

08:47 EDT Orbit International's Electronic Group reports Q2 bookings in excess of $3.25M - Orbit International reported bookings in excess of $3,250,000 for the second quarter of 2021. Deliveries for certain of these orders have already commenced and are expected to continue through the third quarter of 2022.

08:43 EDT GT Biopharma announces sponsored research agreement with Miller worth $2.07M - GT Biopharma announced it has entered into a sponsored research agreement with Jeffrey Miller, M.D., Deputy Director of the University of Minnesota's Masonic Cancer Center and Consulting Chief Scientific Officer of GT Biopharma. The SRA is focused on supporting GT Biopharma's continued clinical develop of TriKE therapeutic product candidates, and to gain an increased understanding of changes in the patient's native NK cell population as a result of TriKE therapy. The SRA is a fixed sum contract worth $2,074,686 payable over the next two years in equal quarterly payments. GT Biopharma has early termination rights without financial penalty, and will receive an exclusive worldwide license to any patentable inventions which arise under the SRA.

08:40 EDT Digital Ally new healthcare business unit acquires medical billing company - Digital Ally's new healthcare business unit, Digital Ally Healthcare, has acquired a medical billing company located in the Mid-West with annual revenues of approximately $1.0M. This company provides revenue cycle management services for over 40 physician clients in diverse specialties. Digital Healthcare made the acquisition through its joint venture with Nobility, an eight-year old RCM company servicing the medical industry. The purchase price was $1.2M with approximately 70% paid in cash at the closing and the balance through an earn-out promissory note bearing interest at 3% payable over 30 months. The earnout note is subject to adjustment based on future revenues and client retention of the acquired company.

08:38 EDT Glimpse Group appoints Alexander Ruckdaeschel and Maydan Rothblum to Board - Glimpse Group has appointed Alexander Ruckdaeschel as an independent director and Maydan Rothblum, its current CFO, COO and co-founder, as a non-independent director. Ruckdaeschel has worked in the financial industry for over 20 years in the U.S. and Europe and until recently, served on the Board of Directors of Vuzix, a supplier of smart glasses and AR technology products and services.

08:35 EDT Xenon Pharmaceuticals completes patient randomization in Phase 2b XEN1101 trial - Xenon Pharmaceuticals provided an update on its ongoing XEN1101 Phase 2b "X-TOLE" clinical trial, announcing that randomization of 326 patients was completed in late June. Based on completion of patient randomization, Xenon anticipates topline results from the Phase 2b X-TOLE clinical trial in late September to mid-October. XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders. Xenon's "X-TOLE" study is an ongoing Phase 2b clinical trial to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in approximately 300 adult patients with focal epilepsy. The primary endpoint is the median percent change in monthly focal seizure frequency from baseline compared to treatment period of active versus placebo.

08:33 EDT Medigus increases holdings in Gix to 36.7% on a fully diluted basis - Medigus announced that it exercised all of its rights to convert Linkury Ltd. shares to Gix Internet Ltd. shares and was issued 3,954,980 additional ordinary shares of Gix such that following the conversion, Medigus holds approximately 36.7% on a fully diluted basis of Gix outstanding capital. In March 2021, Gix's board of directors has resolved to establish a committee of the board of directors to identify new opportunities and activities to merge with Gix, focusing on technology and other sectors that are not necessarily in the field of online advertising. If a new activity is found and leads to a binding agreement and a merger, Gix Internet will examine the possibility of taking Linkury public and/or distributing its shares as a dividend to Gix's shareholders. In addition, Gix announced, that Linkury has entered into a memorandum of understandings, for the acquisition of a company from the online advertising field. According to Gix's announcement, revenues from this company, expects to be more than NIS 71 million in 2021.

08:29 EDT RBC becomes worldwide partner of 43rd Ryder Cup - The Royal Bank of Canada, or RBC, the PGA of America and Ryder Cup Europe have announced a one-year agreement establishing Canada's biggest bank as a Worldwide Partner of the 2020 Ryder Cup, which takes place September 21-26, 2021, at Whistling Straits in Kohler, Wisconsin. "The Ryder Cup is an iconic event, embodying the very best of golf - bringing a worldwide audience together and creating a special energy and excitement connected to team competition in golf," said Mary DePaoli, Executive Vice-President and Chief Marketing Officer, RBC. "One of the most highly anticipated dates on the global sports calendar, RBC is proud and excited to be a Worldwide Partner of the 43rd Ryder Cup, and to help bring this historic event to RBC clients and golf fans around the world." RBC's partnership with the 43rd Ryder Cup will include prominent on-course branding, a strategic media integration and exclusive onsite hospitality for RBC clients. This hospitality will provide special viewing areas for RBC clients as well as unique golf and event experiences. RBC will also receive prominent broadcast and digital assets, deepening RBC's presence in golf during one of the premier events of the season.

08:25 EDT IBM, Vantiq collaborate to deliver edge solutions at scale - Vantiq announced it will collaborate with IBM to help clients adopt an edge computing strategy designed to enable them to move data and applications seamlessly across hybrid cloud environments, from private data centers to the edge. The combination of IBM Edge Application Manager and Vantiq's low-code platform for real-time systems can help enterprises leverage real-time data to help position them to run smarter businesses.

08:23 EDT VBI Vaccines announces Codiak BioSciences' CFO Linda Bain to join board - VBI Vaccines (VBIV) announced that Linda Bain, Chief Financial Officer of Codiak BioSciences has joined its Board of Directors. Ms. Bain is an accomplished financial and business executive with more than two decades of finance, strategy, and board experience in both small and large public companies in the biotechnology and pharmaceutical industry. As CFO of Codiak BioSciences (CDAK), Bain led the company through its initial public offering and first follow-on financing, building on the success of earlier-stage financing rounds. Ms. Bain plays a lead role in establishing Codiak's strategic direction and she built and leads finance and business operations, including investor relations and corporate communications, finance, accounting, facilities and information technology.

08:23 EDT Trident Acquisitions announces filing of Form S-4 in Lottery.com combination - Trident Acquisitions announced that it has filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4 in connection with its proposed business combination with AutoLotto. Lottery.com and Trident entered into a definitive agreement relating to the business combination on February 21, 2021. Immediately following the business combination and assuming no redemptions by Trident shareholders, Lottery.com expects to have approximately $43 million in cash, which will be used to expand Lottery.com's global digital platform and fund working capital to support the company's growth strategy. Additionally, Lottery.com has completed the previously announced acquisitions of Medios Electronicos y de Comunicacion, S.A.P.I. de C.V and JuegaLotto, S.A. de C.V. Aganar has been operating in the Mexican iLottery market since 2007 and is licensed to sell Mexican National Lottery games online and has access to a federally approved online casino and sportsbook gaming license. JuegaLotto is licensed to sell international lottery games in Mexico though a federal gaming portal and to sell other games of chance throughout Latin America.

08:21 EDT Decibel Cannabis announces partnership with Union Cannabis Group - Decibel Cannabis announces that it entered into a strategic partnership with Union Cannabis Group. Under the strategic partnership, Decibel has gained access to product formulations and intellectual property for the manufacturing of vapes and concentrates. This partnership allows Decibel to acquire the exclusive right to produce these distinct product formulations for its existing brands, as well as, to manufacture and distribute UCG's branded products under the Dabstract brand. "Decibel is committed to continuously raising the bar when it comes to product quality and innovation in the cannabis industry" said Paul Wilson, Chief Executive Officer of Decibel. "This strategic partnership bolsters our product development pipeline in the high growth vape and concentrate product categories while strengthening our brand portfolio by bringing the renowned Dabstract brand to the Canadian marketplace."

08:18 EDT Xperi unit TiVo renews and expands IP license with Google - TiVo, a wholly owned subsidiary of Xperi Holding (XPER) announced a long-term renewal of its patent license with Google (GOOG) . The renewal provides Google, who has been a licensee since 2012, with continued broad coverage under TiVo's patent portfolios. "We are very pleased to conclude this agreement with Google, a world leader in OTT video with YouTube and Google TV, and a top 10 US Pay-TV provider with YouTube TV," said Samir Armaly, president, IP licensing of Xperi. "Google has always worked to bring content to the screen that's most convenient for users. This agreement illustrates the relevance of TiVo's innovations across all forms of video consumption, from linear to on-demand, and from traditional TV platforms to online and mobile." TiVo has spent decades investing in research and development to create market-leading technologies broadly licensing them to the media and entertainment industry. TiVo's innovations make it easier for viewers to find, watch, and enjoy all their content across a multitude of platforms.

08:18 EDT Spark Networks begins monetization of Zoosk Live! - Spark Networks announced that the company has begun to record revenue from Zoosk Live! a livestreaming service offered via a partnership with ParshipMeet Group. The service offers a range of livestreaming options, including challenges, events, and interactive features like NextDate, a speed dating game where Zoosk members can take a starring role in front of a livestreaming audience. Members can also forge connections with people all around the world by publicly commenting on videos and rewarding streamers with likes and follows. The launch of Zoosk Live! marks Spark Networks' initial step into the emerging social discovery sector. "We're excited to bring livestreaming to Zoosk users, allowing them to connect with others in a fun social environment," said Eric Eichmann, CEO of Spark Networks. "This launch reinforces our commitment to exploring new areas of personal connection while beginning our expansion beyond online dating and into the emerging social discovery space."

08:17 EDT The Edge Group announces addition of new preferred supplier ScanSource - The Edge Group announced the addition of ScanSource as the organization's newest preferred supplier. "Having ScanSource as part of the Edge Roster will be very beneficial for the entire group", said Don Koehler, Edge Group's Sr. Vice President of Sales. "The breadth of their line card featuring industry leading suppliers gives the Edge members a complete technology solution to serve their customers."

08:16 EDT LMP Automotive appoints Robert Bellaflores as CFO - LMP Automotive appointment Robert Bellaflores as CFO. Robert Bellaflores has served as Senior Corporate Controller of LMP since April 16. Prior to joining the company, Bellaflores was with the Projects Division of Steven Douglas & Associates from 2006 to 2021 as a senior level executive. Prior to 2006, Bellaflores was the Controller for several public and private companies.

08:15 EDT AutoWeb announces results of comprehensive analysis of AutoWeb, Experian data - AutoWeb announced the results of a comprehensive analysis performed, using a combination of AutoWeb and Experian data, and a pilot program that integrates digital retailing components into AutoWeb's consumer experience. This work reinforces AutoWeb's unique ability to match dealers with high value in-market car buyers. Multiple analyses of AutoWeb's internal data revealed positive insights about its audience segments, demonstrating they are both local and ready-to-buy. With close rates of particular importance to AutoWeb's customers, an internal analysis found AutoWeb's audiences who purchase or lease a vehicle make their purchases quickly-25 percent within four days, 50 percent within eight days and 75 percent within 19 days-making them highly desirable audiences for dealerships with whom to connect. Internal data analysis also found some surprising information about how distance to the dealership factors into a vehicle buyer's purchase. In fact, reports show distance to dealerships was not a strong differentiating factor when vehicle shoppers decide which dealership to purchase from, as there was only just over one mile difference in distance for dealers that secured the sale versus those that did not. Separately, an analysis using Experian data reaffirmed AutoWeb's unique market position. Based on the analysis, AutoWeb's audience segments have a slightly higher than average annual household income at $81,454 and a home ownership rate of 77 percent. In addition, 60 percent have a college degree or completed some college. The data analyses also revealed that AutoWeb's consumer leads scored favorably compared to the general population based on Experian's ConsumerViewSM Profitability Score, which helps identify households likely to pay their debts and ranks households based on profitability, approval rates for financing, response rates to advertisements and other marketing efforts, and likelihood to perform as data suggests. In December 2020, AutoWeb began layering in new retail-ready components to its consumer experience, incorporating them into the thank you page of its lead generation process. In addition to opening the door for further engagement opportunities related to financing and trade-in, this enables AutoWeb to collect additional data to create more tailored profiles of buyers using its sites and enhance their shopping experience. An internal data analysis of these new retail components indicate AutoWeb's consumers are digital-retail-ready. During the first quarter of 2021, 39 percent of consumers presented with this functionality engaged with it, and 9 percent of those completed a secondary digital retailing conversion process-affirming the potential prospects of this element of the company's product evolution. These recent data analyses were conducted as part of AutoWeb's strategic product evolution efforts, which include expanding its data science capabilities. The consumer insights will be key as the company enhances its matchmaking capabilities to better connect in-market shoppers with dealers to achieve strong close rates.

08:14 EDT CEL-SCI issues letter to shareholders regarding Multikine study results - CEL-SCI issued a letter to its shareholders. The letter said, "The purpose of this letter today is to address some confusion regarding the Phase 3 study results we announced last week. In the world's largest Phase 3 study in newly diagnosed advanced primary head and neck cancer, our Multikine(R) (Leukocyte Interleukin, Injection)* immunotherapy produced a statistically significant 14.1% 5-year survival benefit in patients receiving surgery plus radiotherapy, representing 40% of the study population and an estimated 155,000 patients annually. The confusion appears to lie in whether the data, which shows benefit in 1 of the 2 potential treatment arms for our patients can be used for approval. As we will explain here, the analysis for the successful treatment arm was pre-specified in the protocol and conducted before unblinding. This means the data from the successful treatment arm can be used in seeking FDA approval. To be clear: we now have excellent 5-year survival data with no safety issues and we know the use of this data is permitted in seeking FDA approval... Patients receiving Multikine followed by surgery and radiation showed excellent 5-year survival benefit and met and exceeded all the designated parameters set for the protocol for the study to be deemed successful. Per the protocol, these determinations could only be done after at least 298 events (patient deaths) had been reached in the combined comparator arms of the study. If you look at the study protocol you will see that we thought that it might take us about 3 years of follow-up to achieve 298 events, but the significantly slower accumulation of events extended that time frame allowing us to see over 5 years of survival data, which is even better. The 5-year OS benefit was 14.1% in absolute terms exceeding the protocol required 10% or better. The study result's p-value was 0.0236 exceeding the protocol required p-value of less than0.05. The study result's Hazard Ratio was 0.68 exceeding the protocol required 0.721... We have determined that it is possible to select the population that would receive the Multikine benefit at their time of diagnosis. We have vetted this with a number of expert physicians in the field and they agreed with the feasibility of the proposed pre-selection methodology... Some false assertions and misrepresentations have been made and published by parties who either did not understand the protocol and statistical analysis or had ulterior motives pertaining to our stock price. The key false assertion was that CEL-SCI is not permitted to rely on the surgery plus radiation treatment arm on its own to file for FDA approval. I say it clearly: this is absolutely false and incorrect. The surgery plus radiation arm of the study was pre-specified and is in fact one of the 2 potential treatment arms per the NCCN Treatment Guidelines for this disease. Analysis of any of the treatment arms on their own was always a part of the SAP, and it was pre-specified before database lock and before anyone began analyzing the data. To summarize again, all analyses were pre-specified in the protocol and SAP and were performed only following database lock and prior to unblinding to the study data. Therefore, we are permitted to use the Multikine plus surgery and radiation data for FDA approval submission. We intend to seek FDA approval for patients who receive Multikine followed by surgery and radiation. Why should a lack of survival benefit for the treatment arm also receiving chemotherapy have negative ramifications on the approval for the patients who only receive Multikine followed by surgery and radiation? We are talking about a clear long term statistically significant survival benefit in one of the two treatment arms which had 380 patients. This was about 40% of the total study patient population, not some small subgroup of patients who could potentially benefit. Two different and pre-specified treatment arms were given to the patients following surgery and both follow the NCCN Standard of Care Guidelines, one worked really well, while the other one did not. Other false assertions made were that CEL-SCI had the data in our possession for over a year and that we had been "data mining" to find a benefit and "p-value hacking". CEL-SCI did not receive the data until just before we made the announcement and up until that time, we were blinded to it. The p-value of the study was in fact very strong... In closing, our very successful data for the Multikine treatment regimen in patients who received surgery plus radiation treatment eliminates the data risk. Since the analyses were pre-specified in the protocol and the SAP and analyses were done after database lock and before unblinding to the study data, we are allowed to use the data showing robust and durable 5-year overall survival benefit in our FDA submission. No safety issues were identified. We have $47M in the bank. We are now preparing to meet with the FDA for a pre-Biologics License Application (BLA) meeting and seek and file for FDA approval. In talking to experts in the field we hear only positive reactions to our study results. FDA and/or the medical community will look at the clinical impact: improved survival over SOC alone; benefit/risk of the drug; the safety profile (excellent); the statistical calculations (excellent); and also analyze and assess all the results with the knowledge that this is an unmet medical need for which no new treatments have come to market in decades."

08:13 EDT Tenax Therapeutics announces $10M PIPE offering priced at-the-market - The Company announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 4,773,269 Units at a purchase price of $2.095 per Unit. Each Unit consists of one unregistered pre-funded warrant to purchase one share of common stock, par value $0.0001 and one unregistered warrant to purchase one share of common stock. In the aggregate, 9,546,538 shares of the Company's common stock are underlying the warrants. The unregistered pre-funded warrants have an exercise price of $0.0001 per share of common stock, are immediately exercisable, and may be exercised at any time until exercised in full. The unregistered warrants have an exercise price of $1.97 per share of common stock, are immediately exercisable, and will expire five and one-half years from the date of issuance. The aggregate gross proceeds to the Company of the offering are expected to be approximately $10M. The offering is expected to close on or about July 8, 2021, subject to the satisfaction of customary closing conditions. Gerald Proehl, Chairman of the Board of Directors for the Company, said: "We thank Tony for his dedicated service and many contributions to Tenax and wish him the best in his well-deserved retirement from executive management. While we will miss Tony's services and involvement in our Company, this transition will not affect Tenax's focus or direction. We are looking forward to having Chris contribute his extensive experience with bringing pharmaceutical products to market as Tenax's new leader, and to continuing to enhance shareholder value through the development and approval of our products for use by patients suffering from cardiovascular and pulmonologic diseases, which is further supported by the financing we are announcing today."

08:12 EDT Sterling Bancorp makes strategic investment in Verdigris Holdings - Sterling Bancorp has made a strategic investment in Verdigris Holdings, the parent company of BrightFi, a leading provider of digital banking services to banks and non-bank institutions. Founded in 2016, BrightFi delivers cloud-based technology solutions that deploy digital banking and other financial services in a time- and cost-efficient manner. BrightFi partners with regional and community banks, community organizations, employers, retailers, and other institutions to deliver financial services to companies and consumers in communities under banked and underserved by more traditional financial institutions.

08:12 EDT Abry Partners, Hoplon announce completion of Concentrix's Insurance acquisition - Abry Partners and Hoplon Capital announced the completion of their acquisition of Concentrix Corporation's insurance third-party administration and software platform. Concurrent with the transaction, the independent stand-alone insurance administration and software services company has been re-branded as illumifin and will be led by newly-appointed Chief Executive Officer Phil Ratcliff.

08:09 EDT Sono-Tek launches new program for Roll-to-Roll coating equipment - Sono-Tek Corporation announced the launch of a new program for the development of Roll-to-Roll coating equipment for the manufacturing of high volume proton-exchange membrane fuel cells. Development will be accelerated by a partnership agreement with a company that has a proven track record for successfully implementing the highest level of PEM production with premier fuel cell companies. In addition, there are several milestones of achievement written into the partnership agreement which are expected to allow for significant product enhancements to be released to the Sono-Tek customer base during the development process. The program is expected to take approximately 2 years to complete. As previously disclosed, Sono-Tek is projecting record revenue in fiscal year 2022, ending February 28, 2022.

08:08 EDT Milestone Scientific commences sales of CompuFlo/CathCheck to UTMB - Milestone Scientific reported that the University of Texas Medical Branch Health Clear Lake Campus Hospital has begun use of the CompuFlo Epidural Instrument. UTMB is an institution of the University of Texas System and agency of the State of Texas. UTMB is a major academic health sciences center of global influence, with medical, nursing, health professions and graduate biomedical schools; a world-renowned research enterprise; and a growing, comprehensive health system with hospitals on four campuses. As previously announced, Milestone had begun selling CompuFlo disposables to the UTMB Health Galveston Campus Hospital.

08:08 EDT Vivos Therapeutics' dental tissue treatment shows 97% satisfaction in study - Vivos Therapeutics has unveiled new data from an independent patient survey related to its proprietary Vivos treatment for treating dental tissue anomalies and dentofacial malformations known to be associated with obstructive sleep apnea - OSA - and other debilitating health conditions. Key findings include: nearly all - 97 percent - of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA. 29% of patients surveyed said that they searched for non-surgical alternatives to current standards of care for treating OSA. The Vivos treatment is typically completed in approximately 12 to 24 months, after which most patients no longer require ongoing intervention.

08:07 EDT AerCap leased, purchased, sold 78 aircraft in second quarter - AerCap Holdings has announced its major business transactions during the second quarter 2021: signed lease agreements for 51 aircraft, including 13 widebody aircraft and 38 narrowbody aircraft; purchased 15 aircraft, including 10 Airbus A320neo Family aircraft, 4 Boeing 737 MAX aircraft and 1 Embraer E2; and executed sale transactions for 12 aircraft, including 1 Airbus A330, 5 Boeing 737NGs, 3 Boeing 757s and 3 Boeing 767-300ERs from AerCap's owned portfolio.

08:06 EDT Axalta Coating to acquire U-POL for $590M - Axalta Coating Systems announced that it has entered into definitive agreements to acquire U-POL Holdings Limited from Graphite Capital Management LLP and other holders for GBP 428M, or approximately $590M, subject to certain adjustments set forth in the Sale and Purchase Agreements for the transaction. "Axalta is the world leader in the premium refinish coatings segment. U-POL's expertise in refinish accessories and protective coatings is highly complementary to Axalta's business and expands our addressable market into the important and growing mainstream and economy-based refinish segment as well as the consumer do-it-yourself aftermarket," said Robert Bryant, Axalta's CEO. "We also see opportunities for U-POL's technology in whitespace applications for other areas of our business, including Mobility and Industrial Coatings." U-POL expects net sales of approximately $145M and adjusted EBITDA of approximately $38M for fiscal year 2021. Axalta expects to realize meaningful operating and commercial synergies across the combined global businesses. Expected annual operating synergies and efficiencies of approximately $10M are expected to be fully realized within 18 to 24 months of close. Axalta plans to finance the transaction from cash on hand. The transaction is expected to close in the second half of 2021, subject to clearance under applicable antitrust laws and other customary closing requirements.

08:06 EDT BigCommerce teams with Amazon MCF for to fulfill ecommerce orders - BigCommerce(BIGC) announced a new integration with Amazon (AMZN) Multi-Channel Fulfillment MCF that allows BigCommerce U.S. merchants to more easily fulfill their ecommerce orders using Amazon's order fulfillment services whether they sell on Amazon or not. "Adding Amazon MCF to our best-in-class tech partner portfolio brings tremendous value to our merchants by strengthening their omnichannel strategy to enhance their competitive edge and deliver a superior online shopping experience at every touchpoint," said Sharon Gee, general manager of Omnichannel, BigCommerce. "Convenience and fast shipping expectations have become the holy grail of the online shopper with demand forecasting becoming harder to control. Amazon MCF will help our merchants to better plan, purchase and fulfill in a much more efficient way than they've ever been able to do before." With MCF, BigCommerce merchants have access to Amazon's world-class fulfillment network, operational expertise, fast ship speeds and lower fulfillment costs with competitive rates and scalable capacity.

08:03 EDT United Community Banks completes acquisition of FinTrust Capital Partners - United Community Banks has completed its acquisition of FinTrust Capital Partners and its operating subsidiaries FinTrust Capital Advisors, FinTrust Capital Benefit Group and FinTrust Brokerage Services. FinTrust is a 13-year-old investment advisory firm headquartered in Greenville, South Carolina, with additional locations in Anderson, South Carolina, and Athens and Macon, Georgia. The firm provides wealth and investment management services to individuals and institutions within its markets. As of March 31, FinTrust had AUM of $2.0B across its advisory, retirement planning and brokerage businesses. On a combined basis, United now has $4.4B in AUM or advisement. FinTrust will become an operating subsidiary of United and certain businesses currently operating under the Seaside brand will be combined with FinTrust and its existing brand. FinTrust's Managing Partners, Phillip Brice, Pat Sheridan, and Allen Gillespie and their team will continue to operate the business.

07:58 EDT Dare Bioscience announces $49M grant from Bill & Melinda Gates Foundation - In a regulatory 8-K filing, the company states: "On June 30, 2021, Dare Bioscience entered into an agreement with the Bill & Melinda Gates Foundation, under which we were awarded a new grant of up to $48.95M to support the development of DARE-LARC1, our investigational user-controlled, long-acting reversible contraceptive. The Grant will support technology development and preclinical activities to advance DARE-LARC1 toward clinical testing in humans over the period of June 30, 2021 to November 1, 2026. We will receive an initial payment of $11.45 million in July 2021. Additional payments under the Grant Agreement are contingent upon the DARE-LARC1 program's achievement of specified development and reporting milestones during the Grant Period." Shares of Dare Bioscience are up over 46% at $2.23 in pre-market trading.

07:49 EDT Lexagene Holdings launches second-generation MiQLab Bacterial, AMR Panel - LexaGene Holdings announced the release of its second-generation MiQLab Bacterial and AMR Panel. LexaGene's first Bacterial and AMR Test screened samples for seven different pathogens and 13 different antimicrobial resistance factors. This first panel was largely built around pathogens and resistance genes commonly encountered in urinary tract infections, and was well-received within the veterinary community. LexaGene's 2nd generation assay panel, taking advantage of the platform's capacity for new targets, was expanded at the request of veterinarians to improve coverage for pathogens that cause other common types of infections, namely skin, soft tissue, and wound infections, and ear infections. LexaGene's Bacterial and AMR Test Version 2 screens for 10 pathogens and 35 genes and variants, that confer antimicrobial drug resistance, a 140% and 270% increase, respectively, from the Company's first-generation test. The new test is expected to detect 96 percent of bacterial UTIs and 93 percent of bacterial SSTIs, and detect a much higher percentage of genes that confer resistance to some of the most commonly prescribed antibiotics.

07:47 EDT Adagene board authorizes share repurchase program up to $20M - Adagene announced that its board of directors has authorized a share repurchase program under which, Adagene may repurchase up to $20M of its ordinary shares in the form of American depositary shares, subject to the relevant rules under the Securities Exchange Act of 1934, as amended, and the Company's insider trading policy.

07:39 EDT Ayr Wellness launches Seven Hills flower in Pennsylvania - Ayr Wellness announced the launch of its Seven Hills flower in Pennsylvania. The launch of Seven Hills follows the introduction of Revel branded flower in May. Seven Hills is first offering from our hybrid-greenhouse facility located in Pottsville, PA. Sales of Seven Hills flower begin today and will launch exclusively in the Ayr Wellness dispensaries in Plymouth Meeting, New Castle, and Gibsonia, Pennsylvania. Wholesale to other dispensary operators in the Commonwealth will begin later this month.

07:37 EDT Silverback in supply pact with Regeneron to evaluate SBT6050/Libtayo combo - Silverback Therapeutics (SBTX) announced a clinical supply agreement with Regeneron (REGN) for Libtayo, cemiplimab. The supply agreement supports the evaluation of Libtay, a PD-1 inhibitor, in combination with SBT6050, the first of a new class of targeted immuno-oncology agents designed to direct a TLR8 agonist linker-payload to activate myeloid cells in tumors expressing moderate to high levels of HER2. "SBT6050's unique ability to activate both innate and adaptive immune responses has the potential to enhance and expand the effectiveness of a PD-1 inhibitor in HER2-expressing solid tumors," said Naomi Hunder, M.D., Chief Medical Officer of Silverback. "We are eager to complete the ongoing dose escalation of SBT6050 combined with a PD-1 inhibitor, and look forward to working with Regeneron as we begin tumor-specific expansion cohorts." In the first quarter of 2021, Silverback initiated treatment in Part 3 of the Phase 1/1b study to evaluate the activity of SBT6050 in combination with a PD-1 inhibitor in dose escalation. Under the terms of the agreement, Silverback will expand the ongoing Phase 1/1b trial to evaluate the combination of SBT6050 and Libtayo in tumor-specific dose expansion cohorts, initially in HER2-expressing non small cell lung cancer and gastric cancer. Libtayo is a PD-1 blocking antibody being jointly developed and commercialized by Regeneron and Sanofi.

07:36 EDT GoGold Resources reports production for most recent quarter - GoGold Resources reports production for the quarter ending June 30, 2021 of 575,302 silver equivalent ounces, consisting of 315,632 silver ounces, 3,170 gold ounces, and 120 tonnes of copper. Parral has generated positive free cash flow for ten consecutive quarters, with estimated free cash flows exceeding $5.5M this quarter. "Parral continues to be an engine of free cash flow, generating in excess of $5.5M this quarter. We finished the quarter with a strong cash balance of over $73M US," said Brad Langille, President and CEO. "Parral's free cash flow, when reinvested in Los Ricos, is creating exceptional value growth for our shareholders"

07:34 EDT ZW Data Action Technologies partner with VCan Fintech for e-commerce solutions - ZW Data Action Technologies has signed a strategic cooperation agreement with VCan Fintech, a Hong Kong-based financial technology company for global payment solutions. VCan provides global financing and payment solutions for cross-border e-commerce merchants. The two companies will start in-depth cooperation in three major aspects of business, operation, and technology. In the business aspect, they will build data interfaces with VCan and integrate advertising and marketing business. In the operation aspect, through VCan's regulatory licenses, they expect to launch an integrated cross-border payment service platform. In the technology aspect, they expect to build a B2B cross-border payment platform backed by blockchain technology.

07:32 EDT Belden provides update on November 2020 data breach incident - As was first communicated on November 24, 2020, Belden Inc. was the victim of a cyber-attack that may have exposed the personal information of current and former employees and some of their spouses, dependents, and relatives, and limited company information regarding some business partners. THe company said, "On the evening of November 12, 2020, Belden IT professionals detected unusual activity involving certain company servers. We immediately triggered our cybersecurity incident response plan, deployed teams of internal IT specialists, and engaged leading third-party cybersecurity forensic experts and other advisors to identify the scope of the incident and move quickly to mitigate the impact. Forensics experts determined that we were the target of a sophisticated attack by a party outside the company. In addition to containing personal information of some current and former employees, we subsequently learned that our servers also contained some health-related information of some current and former employees, as well as some personal and health-related information of some spouses, dependents, and relatives of some current and former employees. The personal and health-related information involved in this incident may have included names, birthdates, government-issued identification numbers (for example, social security number), bank account information (for North American employees on Belden payroll), home addresses, email addresses, other general employment-related information (for Belden employees), gender, and benefits information, such as UMI (member) number, group number, coverage category, primary source of coverage, the effective date of that coverage, any additional sources of coverage, the effective date of additional coverages, their relationship to a Belden employee, and other benefits information. For individuals involved in a workers' compensation claim associated with Belden, the personal and health-related information may have also included some information about their injury. For Belden personnel in insurance claims dispute discussions, the information about them may have included diagnosis and treatment information related to the claim. Otherwise, Belden personnel do not have access to individuals' diagnosis and treatment information. As we have previously stated, our investigation into this incident is ongoing. However, we are confident that we have stopped further unauthorized access of personal and health-related data on our servers. In addition to notifying law enforcement and regulatory authorities, we are continuously monitoring for any suspicious activity on our systems and have deployed additional resources to reinforce the security of our systems. For individuals impacted by the incident for whom we had addresses, notification letters have been sent to the most recent addresses available for those impacted by the incident. The letters contain information about identity monitoring services Belden is making available to mitigate the potential impact of this incident."

07:28 EDT Big Cypress announces submission of S-4 for combination with SAB Biotherapeutics - Big Cypress Acquisition announced the confidential submission with the U.S. Securities and Exchange Commission of a draft registration statement on Form S-4 relating to its previously announced proposed business combination with SAB Biotherapeutics. "Submitting the draft S-4 registration statement marks another milestone on our path to successfully completing our planned merger with SAB Biotherapeutics," said Samuel Reich, CEO of Big Cypress Acquisition Corp. "SAB continues to make excellent progress in advancing its clinical programs, announcing last week the start of a Phase 2a challenge study for its therapeutic candidate for seasonal influenza, which hospitalizes about half a million Americans in a typical year and results in up to 60,000 deaths. Additionally, recent increases in COVID-19 infections associated with the powerful Delta and other emerging variants make the ongoing U.S. government-sponsored Phase 2/3 adaptive trial of SAB's novel therapeutic candidate for COVID-19 all the more relevant. We look forward to continuing advances in these and other SAB pipeline programs in the coming months."

07:26 EDT Biohaven Pharmaceutical announces preliminary Q2 revenue for NURTEC ODT - Biohaven Pharmaceutical announced preliminary net product revenue of NURTEC ODT for the second quarter of 2021. Based on preliminary unaudited financial information, the company reported $93M in net product revenue from sales of NURTEC ODT in the second quarter of 2021. Total prescriptions of NURTEC ODT from product launch to date were over 750,000, with approximately 38,000 unique prescribers. Vlad Coric, M.D., CEO of Biohaven commented, "We are thrilled to report preliminary net product revenue of $93 million for NURTEC ODT in the second quarter that continues to exceed expectations and demonstrates the impact that NURTEC ODT is having on patients with migraine. During the quarter, we saw robust growth of NURTEC ODT in the acute treatment of migraine and initial strong growth in the preventive treatment of episodic migraine in the last few weeks after receiving the prevention approval from the FDA. As the first and only dual-therapy medication indicated to both treat and prevent migraines, NURTEC ODT is redefining the treatment paradigm for patients."

07:24 EDT Solaris Resources provides update from drilling at Warintza Project - Solaris Resources reports the latest assay results from ongoing resource expansion drilling at its Warintza Project in southeastern Ecuador. Additional drill holes have extended the strike length of Warintza Central to 1,250m, exceeding the original scope of planned resource drilling across 1,000m of strike length. Warintza Central remains open, with the most recent holes extending mineralization to the east returning some of the strongest intervals reported to date, including SLS-21 and SLS-26. Drilling has consistently shown the highest-grade mineralization at Warintza occurs at or near surface, which lends itself to establishing a robust mine plan with elevated grades benefitting the early years of mine life. To date, 36 holes have been completed at Warintza Central with full assay results reported for 26. Weather conditions have continued to improve at site supporting the continued ramp-up of drilling activities, with increased productivity expected through the third quarter.

07:22 EDT Microbix Biosystems appoints Thomas Scientific as U.S. distributor of QAPs - Microbix Biosystems announces the appointment of Thomas Scientific LLC as distributor of Microbix's quality assessment products for the United States. Under an agreement between the parties, Thomas Scientific has been appointed as the second distributor of Microbix's QAPs in the United States. Thomas Scientific will thereby provide customer service, sales and marketing, distribution, and related logistical support for Microbix's QAPs. Thomas Scientific is one of the largest pure-play scientific distributors in the United States, delivering relevant diagnostic products to healthcare professionals, hospitals, and clinical laboratories to improve the lives of patients. Thomas Scientific provides advanced logistics, including strategically-situated warehousing facilities throughout the territory to enable cost-effective and rapid provisioning.

07:19 EDT Sundial Growers increases commitment to SunStream Bancorp by C$350 - Sundial Growers announced that it has increased its commitment to SunStream Bancorp to C$538M from its previously announced commitment of C$188M.

07:17 EDT LHC Group, SCP Health partner to provide clinical care in the home - LHC Group and SCP Health announced the formation of a strategic partnership to jointly develop and deliver advanced clinical care services in the home. The partnership will provide a comprehensive offering of clinicians covering all aspects of home health care, including skilled nursing facility-at-home and hospital-at-home programs. The new partnership will offer these services to existing and new hospital and health system partners at a time when many providers and patients are increasingly searching for value-based care models and at-home care solutions. The new partnership combines LHC Group's in-home patient care, proprietary data analytics capabilities, clinical modeling, and technologies with SCP Health's clinicians and telehealth capabilities to deliver higher acuity care in the comfort, convenience, and safety of the patient's home. "If this public health emergency has taught us anything, it is that we must all embrace innovative models that allow patients to receive quality care - including more advanced care - at home," said Keith Myers, LHC Group chairman and CEO. "With SCP Health's proven track record for deploying successful models of care to improve patient health and efficiencies, they are an ideal partner for this expansion of our existing SNF at home and hospital-at-home capabilities. Between our skilled nursing and allied health personnel workforce, and SCP Health's network of physicians, we have the 'clinical boots on the ground' ready to implement this innovative program immediately and seamlessly."

07:16 EDT Quest Resource appoints Glenn Culpepper to Board - Quest Resource has elected Glenn Culpepper to its Board of Directors. Culpepper will serve on the Board's Compensation and Strategic Planning Committees. Culpepper has served in senior executive roles and as a director to public and private companies in the environmental services, construction materials, and mining industries. Mr. Culpepper currently serves on the Board of Directors at Wind River Environmental. Previously, he served as CFO at Republic Services, as Senior VP of Newmont Mining and as CFO of Summit Materials.

07:15 EDT NGM Biopharmaceuticals initiates Phase 1/2 study of NGM707 in solid tumors - NGM Biopharmaceuticals has dosed the first patient in a Phase 1/2 study to evaluate the efficacy, safety and pharmacokinetics/pharmacodynamics of NGM707 when given alone or in combination with Keytruda, an anti- PD-1 antibody. NGM707 is a novel dual antagonist antibody that inhibits the Immunoglobulin-like Transcript 2 and Immunoglobulin-like Transcript 4 receptors. NGM707 originated from NGM's in-house discovery engine. ILT2 and ILT4 receptors are implicated in suppressing anti-tumor immune responses and may represent myeloid checkpoints that enable certain tumors to evade immune detection. Preliminary evidence of anti-tumor response in the Phase 2a portion will be evaluated using objective response rate, duration of response and progression free survival, while the Phase 2b portion will also evaluate overall survival. Both the Phase 1 and Phase 2 portions of the study will provide the opportunity to evaluate correlations between biomarker changes and clinical outcomes.

07:12 EDT Scienjoy announces partnership with GFE Foundation to support artists - Scienjoy announced that it has entered into a strategic partnership with the Global Friendship Exchange Foundation, or GFE Foundation, a U.S-based non-profit organization dedicated to supporting young artists from around the world. The partnership will help young artists sell non-fungible tokens from original artwork across various platforms and establish a livestreaming studio in New York. Through the partnership, Scienjoy will support the artists in GFE Foundation's network in their efforts to mint NFTs from original artwork or music for sale and promotion across various platforms, galleries and exhibitions. NFTs are one-of-a-kind tokenized digital assets that are tracked by blockchain. The technology allows artists to create unique artwork tokens, thus enabling the virtual art pieces to be bought and sold similar to physical property. In addition to innovating with NFTs, the partners will open a video livestreaming studio in New York for young artists. The studio will be a place for them to connect with the Scienjoy livestreaming entertainment ecosystem and livestream about their creative process, engage with fans and collectors, and sell and exhibit NFT artwork.

07:10 EDT Trevena begins Olinvyk respiratory physiology study with elderly, obese subjects - Trevena has initiated a new study evaluating the physiologic impact of Olinvyk on respiratory function in elderly / obese subjects. This study expands upon previously published work that the company reported in collaboration with Dr. Dahan's research team. In this study, the integrated inputs of interest are analgesia - benefit - and respiratory depression - risk -. The study aims to recruit ~50% of subjects who are greater than or equal to 65 years old and ~30% of subjects with a BMI greater than 30 kg/m2. Respiratory depression will be assessed using the VRH measure. Analgesia will be measured using the cold pressor test. Enrollment is expected to begin in Q3 2021, and the Company expects to report topline data by year-end 2021.

07:10 EDT Enghouse Systems acquires Momindum SAS - Enghouse Systems announced it has acquired Momindum SAS. Momindum's Enterprise platform allows users to manage, broadcast and augment videos with any type of media. These include in-video hyperlinks, documents, subtitles, chapters and interactive elements such as quizzes and calls to action. The company's patented indexing technology allows keyword search, and videos can be synchronized with documents such as outlines and shared, user-created notes. "Momindum's solution complements our Vidyo offering, while also broadening our video collaboration solutions," said Steve Sadler, Chairman & CEO of Enghouse. "We are very pleased to welcome Momindum's customers, partners and employees to Enghouse."

07:08 EDT Zeta Global appoints Crystal Eastman as CMO - Zeta (ZETA) announced Crystal Eastman as Zeta's first ever CMO. Eastman joins Zeta from The Trade Desk (TTD) where she was head of global marketing and responsible for global go-to-market activities, including product marketing; sponsorships and events; and global campaign activation.

07:07 EDT Atlas Technical Consultants acquires O'Neill Service Group - Atlas Technical Consultants has completed the acquisition of O'Neill Service Group, a construction quality assurance and environmental services firm. With more than 90 employees, OSG delivers technical solutions to transportation, infrastructure, and commercial projects. OSG was formed in 2008 as an environmental and geological services provider in the Pacific Northwest and has since expanded its product offerings to adapt to the demand for support on large scale infrastructure and transit projects. OSG's founder, Dennis O'Neill, will continue to lead the OSG team in coordination with Atlas' senior leadership. Terms of the acquisition were not disclosed. Inclusive of this transaction, the company will have 36,973,313 common shares outstanding, consisting of 32,738,990 class A shares and 4,234,323 class B shares.

07:06 EDT Exela Technologies reports $205M of cash, cash equivalents as of June 30 - Exela Technologies announced that its recently announced $150 million at-the-market equity program has significantly improved its liquidity position by raising $85 million of proceeds. The Company plans to use certain proceeds from the equity program to strategically reduce its debt and associated interest expense obligations as well as explore ways to invest in its growth, in line with the previously announced strategic initiative. As an initial step, Exela intends to target an annual debt service reduction of $25 million. As of June 30, 2021, the Company had over $205 million of cash and cash equivalents. The Company also had $75 million of additional borrowing capacity under various credit facilities, which are available subject to terms and conditions. As a result of the increased liquidity, the Company does not anticipate accessing this additional available borrowing capacity in the near term, including the $53 million available under its $145 million A/R securitization.

07:06 EDT Elys Game Technology to acquire U.S. Bookmaking for $12M in cash, shares upfront - Elys Game Technology announced that it has entered into a definitive purchase agreement to acquire 100% of Bookmakers Company US LLC, a Nevada limited liability company doing business as U.S. Bookmaking, or USB. Founded in 2016, USB is a provider of sports wagering services such as design and consulting, turn-key sports wagering solutions, and risk management. The deal structure provides that, subject to final closing deliveries, which is expected by July 15 or as soon as practicable thereafter, Elys will acquire 100% of USB and USB will become a wholly owned subsidiary of Elys. Pursuant to the terms of the membership interest purchase agreement, Elys will pay $12M on the closing date of which 50% will be payable in cash and 50% in shares of common stock of Elys at a price equal to the volume weighted average price of Elys stock for the 90 trading days preceding the closing date, subject to shareholders approval if the number of shares exceed 4,401,020. In addition, members of USB will have an opportunity to receive up to an additional $38M plus a potential premium of 10% based upon achievement of certain EBITDA milestones during the next four years, payable 50% in cash and 50% in stock at a price equal to the volume weighted average price of Elys common stock for the 90 trading days prior to January 1 of each year during the Earnout period, subject to obtaining shareholder approval described above and a cap on the number of shares to be issued not exceeding 5,065,000. Any excess not approved by shareholders or exceeding the cap shall be paid in cash. The annual Earnout payments are based on the achievement of certain adjusted cumulative EBITDA milestones. The proposed transaction is structured as a membership interest purchase agreement whereby Elys will acquire 100% of USB and USB will become a wholly owned subsidiary of Elys. USB's sellers will receive on the closing date $12M paid 50% in cash and 50% in common shares of Elys and an Earnout of up to $41.8M paid 50% in cash and 50% in common shares of Elys, subject to the shareholder approval requirements and cap described above. Closing of the Proposed Transaction is conditional on the satisfactory completion of due diligence, and if required, the approval of Elys's shareholders and Nasdaq. Each of the parties boards of directors have unanimously approved the membership interest purchase agreement and the proposed transaction on a preliminary basis, with consummation of the closing being subject to satisfactory fairness opinion and satisfactory due diligence, among other conditions. There can be no assurance given that the proposed transaction will occur.

07:05 EDT Builders FirstSource divests Eastern U.S. Gypsum Distribution Operations - Builders FirstSource announced that it has entered into a definitive agreement to sell the assets of its standalone Eastern U.S. Gypsum Distribution Operations to L&W Supply. L&W will acquire all the assets of the Eastern Gypsum Operations, assume the real estate leases for those operations and hire substantially all of the employees at its locations. ABC Supply acquired Chicago-based L&W Supply in 2016. Builders FirstSource entered into the gypsum business through the acquisition of Probuild on July 31, 2015. The Company's Eastern Gypsum Operations consist of 21 facilities located throughout the Northeast and Southeast U.S. which generated sales of approximately $160 million in 2020. This divestiture is aligned with Builders FirstSource's long-term strategy and focus on pursuing strategic growth initiatives in its core value-added business. L&W will provide the employees and customers of the Eastern Gypsum Operations with a reliable partner in the space that can provide both employment opportunities and high-quality service. The sales price of the transaction was not disclosed. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2021.

07:04 EDT Calibre Mining advances Eastern Borosi Project ahead of schedule - Calibre Mining is pleased to provide drill results, and an update on the progress at its 100% owned Eastern Borosi Project located in northeastern Nicaragua. Calibre is advancing the high-grade open pit, and underground resource zones at EBP to provide mill feed to the Libertad mill which currently has 50% surplus capacity. Highlight Infill Drill Results: Guapinol Open Pit: 9.07 g/t Au and 19.9 g/t Ag over 6.5 metres ETW from 216.0 metres; 25.90 g/t Au and 15.3 g/t Ag over 1.9 metres ETW from 163.0 metres; 22.70 g/t Au and 25.5 g/t Ag over 1.8 metres ETW from 160.7 metres. Vancouver Open Pit: 6.42 g/t Au and 14.1 g/t Ag over 7.1 metres ETW from 32.4 metres; 4.46 g/t Au and 39.7 g/t Ag over 4.8 metres ETW from 79.9 metres. Riscos De Oro Underground: 26.49 g/t Au and 99.4 g/t Ag over 2.2 metres ETW from 313.3 metres; 7.76 g/t Au and 186.0 g/t Ag over 2.9 metres ETW from 284.0 metres; 3.18 g/t Au and 262.2 g/t Ag over 8.2 metres ETW from 204.0 metres. Completed 75% of the infill, metallurgical, geotechnical, and hydrological drilling; Additional Guapinol drill results are pending from infill holes completed in the vicinity of previously drilled holes in the core of the high-grade shoot that assayed: 14.39 g/t Au and 14.51 g/t Ag over 6.03 metres, 25.66 g/t Au and 35.19 g/t Ag over 4.81 metres and 26.48 g/t Au and 24.19 g/t Ag over 2.76 metres; Acquired most of the required surface rights; Advanced social, technical, environmental work including; Guapinol/Vancouver open pit design, site layout and infrastructure plans; Riscos de Oro underground mine design specialists engaged. Over 20 new gold targets have been identified across the 176km2 land package with excellent potential to expand known resources and make new discoveries; Previously drilled vein systems that do not currently host resources include the Cadillac Zone which returned drill results including 8.93 g/t Au and 57.4 g/t Ag over 2.6 metres ETW, the San Cristobal Zone: 10.92 g/t Au and 859.0 g/t Ag over 5.7 metres ETW and the Veta Loca Zone: 10.15 g/t Au and 6.9 g/t Ag over 5.4 metres ETW. Resource expansion drilling to begin Q3, 2021.

07:01 EDT Bausch Health subsidiary completes enrollment in second MOJAVE study - Bausch + Lomb, a global eye health business of Bausch Health and Novaliq, announced the second of two Phase 3 MOJAVE studies evaluating the investigational drug NOV03 as an eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction has been completely enrolled with a total of 622 participants.

06:55 EDT Genesco sends letter to shareholders ahead of annual meeting - Genesco sent a letter to shareholders in connection with its 2021 annual meeting of shareholders, to be held on July 20. The company outlined the letter as follows: "Genesco's successful execution of its strategic plan, as evidenced by the Company's share price performance, which has increased by 99% year-to-date, significantly outperforming Genesco's peer index (79%) and the Russell 2000 (17%) over the same period. The strong support received from leading proxy advisory firm ISS recommending shareholders vote "FOR ALL" nine of Genesco's nominees, as well as continued support from analysts, and other third parties. Significant work Genesco has done to intentionally refresh the Board and management team to ensure leadership expertise in areas that are critical to the growth and evolution of the business and to support future value creation. The risk Legion Partners' unqualified nominees would introduce to shareholders, given the lack of principal footwear, public company CEO or CFO, substantial eCommerce, or public board experience to serve on Genesco's Board. Genesco urges shareholders not to be misled by Legion's self-serving campaign for unwarranted change and to vote the BLUE proxy card FOR ALL the Company's highly qualified and experienced director nominees. Shareholders are reminded that their vote is important, no matter how many or how few shares they own. Voting the WHITE proxy card, even in protest, will revoke any previous proxy submitted using the BLUE proxy card. Only the latest-dated proxy counts."

06:40 EDT Babcock & Wilcox announces four-year senior financing facility - Babcock & Wilcox Enterprises announced that on June 30, 2021, it entered into agreements with PNC Bank and an affiliate of MSD Partners under which PNC has provided an up to $50M asset-based revolving credit facility and availability for up to $125M of letters of credit to B&W, and MSD Partners will provide cash collateral to support the letter of credit availability. The Financing Agreements have a maturity date of June 30, 2025. All obligations under the Company's prior Credit Agreement with Bank of America N.A. as administrative agent have been discharged, and the Credit Agreement has been terminated. Under the terms of the prior Credit Agreement, approximately $9M in deferred fees have been waived due to the Company's successful refinancing prior to July 1, 2021.

06:39 EDT SolarWinds announces gold sponsorship of Service Management World - SolarWinds announced its gold sponsorship of Service Management World, July 21-22, 2021. SolarWinds Head Geek Chrystal Taylor will deliver a technical session on service desk monitoring and automation and a video discussion group on service management metrics. The company will also showcase SolarWinds Service Desk, an IT service management product, in its virtual booth.

06:34 EDT Athena Technology Acquisition announces business combination with Heliogen - Athena Technology Acquisition Corp. and Heliogen announced that they have entered into a definitive agreement for a business combination. Following the business combination, Athena expects to be renamed "Heliogen, Inc." and will remain listed on the New York Stock Exchange under the new ticker symbol "HLGN". Heliogen's modular, AI-enabled, concentrated solar power plants have the potential to revolutionize the energy market by alleviating intermittency issues associated with renewable sources of power generation. Heliogen's technology is designed to flatten the power generation curve by using concentrated solar power with storage to increase the availability of energy to industry. The Company's proprietary heliostat layout and control system facilitate concentration of the sun's rays and has the ability to generate temperatures at the point of focus that can exceed 1,000 degrees centigrade. This heat can then be captured and converted for industrial use, power generation, or to produce green hydrogen fuel, with the goal of providing near-24 hour renewable energy that could replace fossil fuels with concentrated sunlight. Heliogen is commencing the commercialization of its AI-enabled, concentrated solar power modules with internationally recognized customers in the industrial, mining, and energy sectors. Athena, led by Chairwoman Isabelle Freidheim and CEO Phyllis Newhouse, is one of the only entirely women-led SPACs, with a diverse, all-female team of managers, advisors and investors. Heliogen's leadership will remain intact immediately after closing, with Bill Gross continuing as CEO of the combined company. Mr. Gross will work alongside Heliogen's current executive team. Phyllis Newhouse is anticipated to join the Board of Directors of the combined company, which will include representation from both Heliogen and Athena. The business combination is structured as a statutory merger of Athena and Heliogen, with Heliogen surviving the merger as a wholly owned subsidiary of Athena. All of Heliogen's stockholders are expected to rollover their equity into the combined company and to receive shares of Athena Class A common stock at closing as consideration. The transaction is anticipated to generate gross proceeds of up to approximately $415M of cash, assuming no redemptions by Athena's public stockholders. The proceeds are expected to be used to scale heliostat manufacturing, to support research and development efforts on next generation heliostat technology, to support global project development, and to fund the balance sheet. These gross proceeds include investor commitments to purchase up to $165M in shares of stock in Athena at $10.00 per share through a private investment in public equity, subject to satisfaction of customary closing conditions. Assuming no redemptions by Athena's public stockholders and including anticipated proceeds from the PIPE, Athena estimates an initial pro forma implied enterprise value of the combined company immediately after closing of the business combination of approximately $2B. The transaction has been unanimously approved by the boards of Heliogen and Athena. Completion of the proposed transaction is subject to customary closing conditions, including the approval of Athena's and Heliogen's respective stockholders and regulatory approvals, and is expected to occur in the fourth calendar quarter of 2021.

06:19 EDT HyperX, Champion announce Glow in the Dark apparel collection - HyperX, the gaming peripherals team at HP Inc. (HPQ), announced a third, limited-edition apparel drop with Champion (HBI). The new HyperX x Champion Glow in the Dark Collection includes Powerblend fleece hoodies, Powerblend fleece joggers and cotton T-shirts, all featuring a minimalistic design with glow in the dark accents. The HyperX x Champion(R) Glow in the Dark Collection will be available for purchase on July 14 on Champion.com. The items in the series are available in a range of unisex sizes from S - XXL, with the cotton T-shirt retailing for $30, Powerblend fleece joggers retailing for $60 and Powerblend fleece hoodie retailing for $75.

06:09 EDT Ceragon Networks awarded managed services agreement by network service provider - Ceragon Networks announced it has been awarded a multi-year managed services agreement by a network service provider in the U.S. The service provider focuses on delivering a suite of connectivity services to enterprise customers leveraging its fiber optic network. As part of its growth plans, it recently expanded its offering to include wireless connectivity, broadening its portfolio of broadband access and cloud solutions. The service provider will utilize Ceragon's managed services to improve the performance of its newly acquired wireless network.

06:06 EDT Planet Labs to become publicly traded through merger with dMY IV - Planet Labs and dMY Technology Group, Inc. IV (DMYQ) announced that they have entered into a definitive merger agreement under which Planet will become a publicly-traded company. Upon closing, the combined company will retain the Planet name and be listed on the NYSE under the ticker symbol "PL." The transaction values Planet at a post-transaction equity value of approximately $2.8B. Planet has a proven track record of success, generating over $100 million in revenue in its last fiscal year ended January 31, 2021, and currently serves more than 600 customers across 65 countries, for example: In agriculture, Planet's data helps farmers increase crop yields and revenue, decrease costs such as fertilizer use, and adopt sustainable agriculture practices. Governmental organizations use Planet's data to increase global security and transparency by monitoring threats, responding to emergencies, and enforcing local permitting. In forestry, Planet's data is used to measure and stop deforestation and to monitor sustainability initiatives. In mapping, Planet's imagery helps keep digital maps up to date as the world changes, whether through environmental effects or urban development. Through this transaction, Planet will invest to accelerate its growth by further expanding into existing and new markets, as well as building additional software and machine-learning-enabled data products and solutions. The transaction values Planet at a post-transaction equity value of approximately $2.8B. Existing Planet stockholders will retain 77% ownership in the pro forma company and may receive up to an additional 27 million new Planet shares, depending on the performance of the share price during the five year period following the closing. Concurrently with the consummation of the transaction, additional investors have committed to participate in the proposed business combination by purchasing shares of Class A common stock of dMY IV in a private placement. The $200 million PIPE investment is led by funds and accounts managed by BlackRock (BX), with participation from Koch Strategic Platforms, Marc Benioff's TIME Ventures, and Google (GOOG, GOOGL). After paying transaction expenses and paydown of Planet's existing debt, the balance of the $345M in cash held in dMY IV's trust account, together with the approximately $200 million in PIPE proceeds, will be used to fund operations and support new and existing growth initiatives. The transaction, which has been unanimously approved by dMY IV's Board of Directors and Planet's Board of Directors, is expected to close later this year, subject to approval by dMY IV's and Planet's stockholders and other customary closing conditions. Planet's management team, led by CEO, Co-Founder and Chair Will Marshall and Chief Strategy Officer, Co-Founder and Director, Robbie Schingler, CFO/COO Ashley Johnson and President, Product and Business Strategy, Kevin Weil, will continue to lead the public company following the transaction. Additionally, dMY IV will nominate one director to serve on the board of directors of the public company following the transaction, with such director being reasonably acceptable to Planet.

06:05 EDT Check Point expanding unified cloud support for Alibaba Cloud - Check Point is extending its multi-cloud support through the integration of Check Point CloudGuard with Alibaba Cloud, the digital intelligence and technology backbone of Alibaba Group. Check Point CloudGuard Posture Management enables organisations to visualise and assess their cloud security posture across various platforms including Alibaba Cloud, and detect and remediate misconfiguration. Check Point is also extending its existing Check Point CloudGuard Network Security capabilities to include availability and management for Alibaba Cloud with threat prevention managed by unified security management.

05:50 EDT Royal Dutch Shell sees Q2 integrated gas production 900,000-960,000 boepd - Sees Q2 LNG liquefication volumes 7.1M-7.7M tons. Sees Q2 trading and optimization results significantly below average. Sees Q2 underlying opex $400M-$500M. Sees Q2 pre-tax depreciation $1.3B-$1.4B. Sees Q2 taxation charge $300M-$600M. The company said, "As a result of strong operational and financial delivery, combined with an improved macro-economic outlook, Shell will move to the next phase of its capital allocation framework and, subject to final Board approval, increase total shareholder distributions to within the range of 20-30% of CFFO, starting at the Q2 results announcement. The level of additional distributions will be determined with full visibility of the Q2 financial results. In the second quarter, Shell expects to have further reduced its net debt, although the extent of the reduction will be moderated by working capital movements. In conjunction with the increased distributions, Shell will retire its net debt milestone of $65 billion and will continue to target further strengthening of its balance sheet and AA credit metrics. 2021 cash capex will remain below $22 billion."

05:42 EDT Immatics enters TCRs collaboration with BioCopy - BioCopy announced a collaboration with Immatics in the field of characterization of T cell receptors, or TCRs. T cell receptors and their interactions with peptide-HLA complexes play a crucial role for the human immune system in the recognition of tumors, among other things.

05:37 EDT Philips enrolls first patient in WE-TRUST study - Philips announced that the first patient has been enrolled in the WE-TRUST study at Vall d'Hebron University Hospital, Barcelona, Spain, marking the official start of this multicenter randomized controlled trial to assess if the Direct to Angio Suite workflow can improve outcomes for early time-window stroke patients. The WE-TRUST trial will study the clinical impact of the Direct to Angio Suite approach, enabled by a special scan in the angio suite developed by Philips. This approach combines stroke diagnosis and subsequent treatment in the same angio suite, which the study will compare to the conventional workflow of diagnosing patients for treatment in the CT or MRI suite and then treating them in a separate angio suite. The Direct to Angio Suite approach can potentially reduce the time to treatment for early time-window stroke patients for whom every second counts. WE-TRUST will be the first global multicenter randomized controlled trial to assess the impact of the Direct to Angio Suite approach. Besides this clinical trial for early time-window stroke patients, Philips is committed to optimizing the care pathway for stroke patients in general.